Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, North Carolina.
Microb Drug Resist. 2020 Jan;26(1):1-8. doi: 10.1089/mdr.2019.0202. Epub 2019 Aug 8.
is a member of the complex whose members are inherently resistant to many antibiotics and can cause chronic lung infections in patients with cystic fibrosis. A possible treatment for chronic infections arises from the existence of collateral sensitivity (CS)-acquired resistance to a treatment antibiotic results in a decreased resistance to a nontreatment antibiotic. Determining CS patterns for bacteria involved in chronic infections may lead to sustainable treatment regimens that reduce development of multidrug-resistant bacterial strains. CS has been found to occur in , , and . Here, we report that exhibits antibiotic CS, as well as cross-resistance (CR), describe CS and CR networks for six antibiotics (ceftazidime, chloramphenicol, levofloxacin, meropenem, minocycline, and trimethoprim-sulfamethoxazole), and identify candidate genes involved in CS. Characterization of CS and CR patterns allows antibiotics to be separated into two clusters based on the treatment drug to which the evolved strain developed primary resistance, suggesting an antibiotic therapy strategy of switching between members of these two clusters.
是 复合体的成员，该复合体的成员对许多抗生素具有固有抗性，并可导致囊性纤维化患者的慢性肺部感染。慢性感染的一种可能治疗方法源于存在协同敏感性（CS）-对治疗抗生素的获得性耐药导致对非治疗抗生素的耐药性降低。确定与慢性感染相关的细菌的 CS 模式可能会导致可持续的治疗方案，从而减少多药耐药细菌菌株的产生。已经发现 CS 存在于 、 和 中。在这里，我们报告 表现出抗生素 CS 以及交叉耐药性（CR），描述了六种抗生素（头孢他啶、氯霉素、左氧氟沙星、美罗培南、米诺环素和复方磺胺甲噁唑）的 CS 和 CR 网络，并确定了与 CS 相关的候选基因。CS 和 CR 模式的特征分析可将抗生素分为两组，基于进化菌株对主要耐药的治疗药物，这表明抗生素治疗策略可以在这两组成员之间切换。
